Active Bladder Cancer Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Bladder Cancer Clinical Trial?

• Find Trials That Fit — Browse recruiting Bladder Cancer trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Bladder Cancer type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Bladder Cancer Clinical Trial FAQ

Are there bladder cancer trials for non-muscle-invasive disease (NMIBC)?

Yes. Trials for non-muscle-invasive bladder cancer (NMIBC) — tumors confined to the inner lining — test intravesical (bladder-instilled) immunotherapy, targeted agents, and novel combinations. BCG-unresponsive NMIBC is a particularly active area, with trials for patients whose cancer did not respond to BCG or who cannot tolerate it.

What bladder cancer trials are available after chemotherapy has stopped working?

Several options exist for platinum-refractory bladder cancer. Immunotherapy (pembrolizumab, atezolizumab), the antibody-drug conjugate enfortumab vedotin, and the FGFR inhibitor erdafitinib (for FGFR3-mutated tumors) are approved and being studied further in trials. Combination trials and novel agents are actively recruiting.

Does my FGFR mutation status matter for bladder cancer trial eligibility?

Yes, for FGFR-targeted trials. FGFR3 mutations are present in about 15–20% of muscle-invasive bladder cancers and a higher proportion of NMIBC. Erdafitinib and other FGFR inhibitors require FGFR3 mutation or fusion. Molecular profiling is increasingly standard for bladder cancer — ask your oncologist if you haven't been tested.

Can I join a bladder cancer trial if I've already had a cystectomy (bladder removal)?

Yes. Many metastatic and systemic therapy trials enroll patients regardless of whether their bladder has been removed. Some adjuvant trials specifically enroll patients after radical cystectomy. The eligibility will depend on your post-surgery pathology and current disease status.

How do I find a bladder cancer trial near me?

Trialify searches ClinicalTrials.gov for recruiting bladder cancer trials and sorts the trial sites by distance from your ZIP code. You answer a few plain-language eligibility questions and get a match summary to share with your urologist or oncologist.

Explore Other Cancer Trial Guides

• Prostate Cancer — Prostate cancer trials are exploring next-generation hormone therapies, PARP inhibitors, radiopharmaceuticals, and novel immunotherapy combinations — including options for castration-resistant disease.
• Kidney Cancer — Kidney cancer trials are evaluating immunotherapy combinations, HIF-2α inhibitors like belzutifan, and novel TKI regimens for clear cell and non-clear cell renal cell carcinoma.
• Lung Cancer — Lung cancer is the leading cause of cancer-related death worldwide. Recruiting clinical trials are testing new immunotherapies, targeted therapies, and combination regimens for NSCLC and SCLC patients.
• Colorectal Cancer — Colorectal cancer trials are evaluating immunotherapy for MSI-H tumors, KRAS and BRAF targeted therapies, and novel combinations for metastatic disease. Many trials enroll both colon and rectal cancer patients.